{"id":"anti-trbv9-monoclonal-antibody-infusions","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Lymphopenia"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Cytokine release syndrome"}]},"_chembl":{"chemblId":"CHEMBL2109418","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TRBV9 is a specific segment of the T-cell receptor beta chain expressed on a subset of T lymphocytes. By binding to TRBV9, this antibody marks these T cells for destruction via antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). This approach selectively targets potentially pathogenic T-cell clones while preserving much of the broader immune repertoire.","oneSentence":"This monoclonal antibody targets and depletes T cells expressing the TRBV9 T-cell receptor beta variable segment, selectively eliminating a subset of pathogenic T cells in autoimmune and T-cell malignancy conditions.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:01:54.990Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"T-cell lymphomas expressing TRBV9"},{"name":"Autoimmune diseases with TRBV9-positive T-cell involvement"}]},"trialDetails":[{"nctId":"NCT06333210","phase":"PHASE3","title":"Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biocad","startDate":"2023-12-25","conditions":"Axial Spondyloarthritis","enrollment":421},{"nctId":"NCT05407779","phase":"PHASE1","title":"Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of Single Escalating Doses of BCD-180 in Healthy Volunteers","status":"COMPLETED","sponsor":"Biocad","startDate":"2021-01-22","conditions":"Healthy","enrollment":39},{"nctId":"NCT05445076","phase":"PHASE2","title":"Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biocad","startDate":"2022-04-19","conditions":"Axial Spondyloarthritis","enrollment":250}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BCD-180 infusions"],"phase":"phase_3","status":"active","brandName":"anti-TRBV9 monoclonal antibody infusions","genericName":"anti-TRBV9 monoclonal antibody infusions","companyName":"Biocad","companyId":"biocad","modality":"Biologic","firstApprovalDate":"","aiSummary":"This monoclonal antibody targets and depletes T cells expressing the TRBV9 T-cell receptor beta variable segment, selectively eliminating a subset of pathogenic T cells in autoimmune and T-cell malignancy conditions. Used for T-cell lymphomas expressing TRBV9, Autoimmune diseases with TRBV9-positive T-cell involvement.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}